KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Financing Activities (2016 - 2025)

Rigel Pharmaceuticals has reported Cash from Financing Activities over the past 16 years, most recently at -$4.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 412.08% year-over-year to -$4.6 million; the TTM value through Dec 2025 reached $601000.0, up 105.16%, while the annual FY2025 figure was $601000.0, 105.16% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$4.6 million at Rigel Pharmaceuticals, down from $4.3 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $59.2 million in Q2 2021 and troughed at -$9.8 million in Q3 2024.
  • A 5-year average of $3.8 million and a median of $451000.0 in 2025 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: surged 1911.31% in 2022 and later tumbled 1032.57% in 2024.
  • Year by year, Cash from Financing Activities stood at $1.1 million in 2021, then plummeted by 293.18% to -$2.1 million in 2022, then surged by 123.19% to $486000.0 in 2023, then skyrocketed by 201.44% to $1.5 million in 2024, then crashed by 412.08% to -$4.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for RIGL at -$4.6 million in Q4 2025, $4.3 million in Q3 2025, and $418000.0 in Q2 2025.